Phase 4 N=65 Prevention

Nasal Decolonization for Orthopedic Trauma Patients

Surgical Site Infection

Bottom Line

View on ClinicalTrials.gov: NCT04146116 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jun 2023

Primary outcome: Primary: Number of Participants With Staphylococcus Aureus Nasal Colonization — 12 Participants

Study Design & Population

Study type: Interventional
Phase: Phase 4
Interventions: intranasal povidone-iodine (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Iowa
Primary completion: Jun 2021

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants With Staphylococcus Aureus Nasal Colonization	2	—
SECONDARY Number of Participants With Staphylococcus Aureus Nasal Colonization	2	—
SECONDARY Number of Participants With Surgical Site Infection	—	—

Summary

Many surgical site infections are caused by bacteria that is transferred from a patient's nose to their open surgical wound. Some small studies have shown that putting povidone-iodine in a patient's nose reduces this risk. This study aims to evaluate the real-world effectiveness of nasal povidone-iodine (PROFEND®) in a group of 50 patients at the University of Iowa.

Eligibility Criteria

Inclusion Criteria

Patients undergoing operative fixation of lower extremity fractures at the University of Iowa during the study period.

Exclusion Criteria

Patients unable to provide informed consent due to head trauma or dementia.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04146116). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.